Immunopathogenesis of primary biliary cirrhosis

Seminars in Liver Disease

Volumn 22, Issue 3, 2002, Pages 291-302

  Nishio, Akiyoshi ^a   Keeffe, Emmet B ^a   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Molecular mimicry; Primary biliary cirrhosis; T cells; Xenobiotics

Indexed keywords

AUTOANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; ESTROGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; MITOCHONDRION ANTIBODY; PYRUVATE DEHYDROGENASE COMPLEX; PYRUVATE DEHYDROGENASE COMPLEX E2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN SPECIFICITY; APOPTOSIS; B LYMPHOCYTE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; EPITHELIUM CELL; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; PATHOPHYSIOLOGY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SALIVARY GLAND DUCT; STAINING; T LYMPHOCYTE;

AUTOANTIBODIES; AUTOANTIGENS; BACTERIAL INFECTIONS; EPITHELIUM; HISTOCOMPATIBILITY ANTIGENS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LIVER CIRRHOSIS, BILIARY; MITOCHONDRIA, LIVER; T-LYMPHOCYTES; VASCULAR CELL ADHESION MOLECULE-1; XENOBIOTICS;

EID: 0036697797     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-34506     Document Type: Review

References (113)

1. Atkinson MA, Bowman MA, Campbell L, et al. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest 1994;94:2125-2129
2. Oomes PG, Jacobs BC, Hazenberg MP, et al. Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barre syndrome: Evidence of molecular mimicry. Ann Neurol 1995;38:170-175
3. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80:695-705
4. Barnaba V, Sinigaglia F. Molecular mimicry and T cell-mediated autoimmune disease. J Exp Med 1997;185:1529-1531
5. Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987;138:3525-3531
6. Coppel RL, McNeilage LJ, Surh CD, et al. Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. Proc Natl Acad Sci USA 1988;85:7317-7321
7. Fussey SP, Guest JR, James OF, et al. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci USA 1988;85:8654-8658
8. Van de Water J, Fregeau D, Davis P, et al. Autoantibodies of primary biliary cirrhosis recognize dihydrolipoamide acetyltransferase and inhibit enzyme function. J Immunol 1988;141:2321-2324
9. Fregeau DR, Davis PA, Danner DJ, et al. Antimitochondrial antibodies of primary biliary cirrhosis recognize dihydrolipoamide acyltransferase and inhibit enzyme function of the branched chain alpha-ketoacid dehydrogenase complex. J Immunol 1989;142:3815-3820
10. Surh CD, Danner DJ, Ahmed A, et al. Reactivity of primary biliary cirrhosis sera with a human fetal liver cDNA clone of branched-chain alpha-keto acid dehydrogenase dihydrolipoamide acyltransferase, the 52 kD mitochondrial autoantigen. Hepatology 1989;9:63-68
11. Surh CD, Roche TE, Danner DJ, et al. Antimitochondrial autoantibodies in primary biliary cirrhosis recognize cross-reactive epitope(s) on protein X and dihydrolipoamide acetyltransferase of pyruvate dehydrogenase complex. Hepatology 1989;10:127-133
12. Fregeau DR, Roche TE, Davis PA, et al. Primary biliary cirrhosis. Inhibition of pyruvate dehydrogenase complex activity by autoantibodies specific for E1 alpha, a non-lipoic acid containing mitochondrial enzyme. J Immunol 1990;144:1671-1676
13. Fregeau DR, Prindiville T, Coppel RL, et al. Inhibition of alpha-ketoglutarate dehydrogenase activity by a distinct population of autoantibodies recognizing dihydrolipoamide succinyltransferase in primary biliary cirrhosis. Hepatology 1990;11:975-981
14. Surh CD, Coppel R, Gershwin ME. Structural requirement for autoreactivity on human pyruvate dehydrogenase-E2, the major autoantigen of primary biliary cirrhosis. Implication for a conformational autoepitope. J Immunol 1990;144:3367-3374
15. Leung PS, Chuang DT, Wynn RM, et al. Autoantibodies to BCOADC-E2 in patients with primary biliary cirrhosis recognize a conformational epitope. Hepatology 1995;22:505-513
16. Moteki S, Leung PS, Dickson ER, et al. Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex. Hepatology 1996;23:436-444
17. Dubel L, Tanaka A, Leung PS, et al. Autoepitope mapping and reactivity of autoantibodies to the dihydrolipoamide dehydrogenase-binding protein (E3BP) and the glycine cleavage proteins in primary biliary cirrhosis. Hepatology 1999;29:1013-1018
18. Fussey SP, Ali ST, Guest JR, et al. Reactivity of primary biliary cirrhosis sera with Escherichia coli dihydrolipoamide acetyltransferase (E2p): characterization of the main immunogenic region. Proc Nad Acad Sci USA 1990;87:3987-3991
19. Leung PS, Iwayama T, Coppel RL, Gershwin ME. Site-directed mutagenesis of lysine within the immunodominant autoepitope of PDC-E2. Hepatology 1990;12:1321-1328
20. Quinn J, Diamond AG, Palmer JM, et al. Lipoylated and unlipoylated domains of human PDC-E2 as autoantigens in primary biliary cirrhosis: significance of lipoate attachment. Hepatology 1993;18:1384-1391
21. Bandin O, Couvalin J, Poupon R, et al. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology 1996;23:1020-1024
22. Wesierska-Gadek J, Honenauer H, Hitchman E, Penner E. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology 1996;110:840-847
23. Szostecki C, Krippner H, Penner E, Bautz FA. Autoimmune sera recognize a 100 kD nuclear protein antigen (sp-100). Clin Exp Immunol 1987;68:108-116
24. Courvalin JC, Lassoued K, Worman HJ, Blobel G. Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis. J Exp Med 1990;172:961-967
25. Krams SM, Van de Water J, Coppel RL, et al. Analysis of hepatic T lymphocyte and immunoglobulin deposits in patients with primary biliary cirrhosis. Hepatology 1990;12:306-313
26. Meuer SC, Moebius U, Manns MM, et al. Clonal analysis of human T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis. Eur J Immunol 1988;18:1447-1452
27. Van de Water J, Ansari AA, Surh CD, et al. Evidence for the targeting by 2-oxo-dehydrogenase enzymes in the T cell response of primary biliary cirrhosis. J Immunol 1991;146:89-94
28. Shimoda S, Nakamura M, Ishibashi H, et al. HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med 1995;181:1835-1845
29. Shimoda S, Van de Water J, Ansari A, et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 1998;102:1831-1840
30. Van de Water J, Ansari A, Prindiville T, et al. Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. J Exp Med 1995;181:723-733
31. Ichiki Y, Shimoda S, Hara H, et al. Analysis of T-cell receptor beta of the T-cell clones reactive to the human PDC-E2 163-176 peptide in the context of HLA-DR53 in patients with primary biliary cirrhosis. Hepatology 1997;26:728-733
32. Kita H, Lian ZX, Van de Water J, et al. Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med 2002;195:113-123
33. Wucherpfennig KW, Catz I, Hausmann S, et al. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J Clin Invest 1997;100:1114-1122
34. Hillaire S, Boucher E, Calmus Y, et al. Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology 1994;107:781-788
35. Ballardini G, Mirakian R, Bianchi FB, et al. Aberrant expression of HLA-DR antigens on bile duct epithelium in primary biliary cirrhosis: relevance to pathogenesis. Lancet 1984;2:1009-1013
36. Adams DH, Hubscher SG, Shaw J, et al. Increased expression of intercellular adhesion molecule 1 on bile ducts in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 1991;14:426-431
37. Ayres RC, Neuberger JM, Shaw J, et al. Intercellular adhesion molecule-1 and MHC antigens on human intrahepatic bile duct cells: effect of pro-inflammatory cytokines. Gut 1993;34:1245-1249
38. Dienes HP, Lohse AW, Gerken G, et al. Bile duct epithelia as target cells in primary biliary cirrhosis and primary sclerosing cholangitis. Virchows Arch 1997;431:119-124
39. Yasoshima M, Nakanuma Y, Tsuneyama K, et al. Immunohistochemical analysis of adhesion molecules in the microenvironment of portal tracts in relation to aberrant expression of PDC-E2 and HLA-DR on the bile ducts in primary biliary cirrhosis. J Pathol 1995;175:319-325
40. Schwartz R. Costimulation of T-lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065-1068
41. Liu Y, Wenger R, Zhao M, Nielsen P. Distinct costimulatory molecules are required for the induction of effector and memory cytotoxic T lymphocytes. J Exp Med 1997;185:251-262
42. Tsuneyama K, Harada K, Yasoshima M, et al. Expression of co-stimulatory factor B7-2 on the intrahepatic bile ducts in primary biliary cirrhosis and primary sclerosing cholangitis: An immunohistochemical study. J Pathol 1998;186:126-130
43. Leon MP, Bassendine MF, Wilson JL, et al. Immunogenicity of biliary epithelium: Investigation of antigen presentation to CD4+ T cells. Hepatology 1996;24:561-567
44. Yashoshima M, Kono N, Sugahara H, et al. Increased expression of interleukin-6 and tumor necrosis factor-α in pathologic biliary epithelial cells: In situ and culture study. Lab Invest 1998;78:89-100
45. Jelnick D, Lipsky P. Enhancement of human B-cell proliferation and differentiation by tumor necrosis factor alpha and interleukin 1. J Immunol 1987;139:2970-2976
46. Matsumoto K, Fujii H, Michalopoulos G, et al. Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: Interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. Hepatology 1994;20:376-382
47. Gonzalez-Amaro R, Garcis-Monzon C, Garcia-Buey L, et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med 1994;179:841-848
48. Mano Y, Ishii M, Okamoto H, et al. Effect of tumor necrosis factor alpha on intrahepatic bile duct epithelial cells of rat liver. Hepatology 1996;23:1602-1607
49. Joplin R, Lindsay JG, Hubscher SG, et al. Distribution of dihydrolipoamide acetyltransferase (E2) in the liver and portal lymph nodes of patients with primary biliary cirrhosis: an immunohistochemical study. Hepatology 1991;14:442-447
50. Van de Water J, Turchany J, Leung PS, et al. Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest 1993;91:2653-2664
51. Joplin R, Wallace L, Lindsay J, et al. The human biliary epithelial cell plasma membrane antigen in primary biliary cirrhosis: Pyruvate dehydrogenase X. Gastroenterology 1996;113:1727-1733
52. Tsuneyama K, Van de water J, Leung PSC, et al. Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histocompatibility complex class II and BB1/B7 expression. Hepatology 1995;21:1031-1037
53. Van de Water J, Gerson LB, Ferrell LD, et al. Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis. Hepatology 1996;24:1079-1084
54. Migliaccio C, Nishio A, Van de Water J, et al. Monoclonal antibodies to mitochondrial E2 components define autoepitopes in primary biliary cirrhosis. J Immunol 1998;161:5157-5163
55. Harada K, Sudo Y, Kono N, et al. In situ nucleic acid detection of PDC-E2, BCOADC-E2, OGDC-E2, PDC-E1alpha, BCOADC-E1alpha, OGDC-E1, and the E3 binding protein (protein X) in primary biliary cirrhosis. Hepatology 1999;30:36-45
56. Danpure CJ. The molecular basis of alanine: glyoxylate aminotransferase mistargeting: the most common single cause of primary hyperoxaluria type I. J Nephrol 1998;11:8-12
57. Nishio A, Van de Water J, Leung PS, et al. Comparative studies of antimitochondrial autoantibodies in sera and bile in primary biliary cirrhosis. Hepatology 1997;25:1085-1089
58. Migliaccio C, Van de Water J, Ansari AA, et al. Heterogeneous response of antimitochondrial autoantibodies and bile duct apical staining monoclonal antibodies to pyruvate dehydrogenase complex E2: The molecule versus the mimic. Hepatology 2001;33:792-801
59. Odin JA, Huebert RC, Casciola-Rosen L, et al. Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J Clin Invest 2001;108:223-232
60. Medina JF, Martinez A, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 1997;25:12-17
61. Kuroki T, Seki S, Kawakita N, et al. Expression of antigens related to apoptosis and cell proliferation in chronic nonsuppurative destructive cholangitis in primary biliary cirrhosis. Virchows Arch 1996;429:119-129
62. Koga H, Sakisaka S, Ohishi M, et al. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 1997;25:1077-1084
63. Harada K, Ozaki S, Gershwin ME, Nakanuma Y. Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis. Hepatology 1997;26:1399-1405
64. Faubion WA, Guicciardi ME, Miyoshi H, et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 1999;103:137-145
65. Parikh-Patel A, Gold E, Mackay IR, Gershwin ME. The geoepidemiology of primary biliary cirrhosis: contrasts and comparisons with the spectrum of autoimmune diseases. Clin Immunol 1999;91:206-218
66. Tsuji K, Watanabe Y, Van De Water J, et al. Familial primary biliary cirrhosis in Hiroshima. J Autoimmun 1999;13:171-178
67. Tanaka A, Borchers AT, Ishibashi H, et al. Genetic and familial considerations of primary biliary cirrhosis. Am J Gastroenterol 2001;96:8-15
68. Arriaga F, Ercilla G, Pares A, et al. Association of HLA-DR3 antigen to disease with immunological components. Sangre (Barc) 1980;25:430-437
69. Gores GJ, Moore SB, Fisher LD, et al. Primary biliary cirrhosis: associations with class II major histocompatibility complex antigens. Hepatology 1987;7:889-892
70. Prochazka EJ, Terasaki PI, Park MS, et al. Association of primary sclerosing cholangitis with HLA-DRw52a. N Engl J Med 1990;322:1842-1844
71. Manns MP, Bremm A, Schneider PM, et al. HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis. Gastroenterology 1991;101:1367-1373
72. Johnston DE, Kaplan MM, Miller KB, et al. Histocompatibility antigens in primary biliary cirrhosis. Am J Gastroenterol 1987;82:1127-1129
73. Miyamori H, Kato Y, Kobayashi K, Hattori N. HLA antigens in Japanese patients with primary biliary cirrhosis and autoimmune hepatitis. Digestion 1983;26:213-217
74. Morling N, Dalhoff K, Fugger L, et al. DNA polymorphism of HLA class II genes in primary biliary cirrhosis. Immunogenetics 1992;35:112-116
75. Begovich AB, Klitz W, Moonsamy PV, et al. Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis. Tissue Antigens 1994;43:71-77
76. Mella JG, Roschmann E, Maier KP, Volk BA. Association of primary biliary cirrhosis with the allele HLA-DPB1*0301 in a German population. Hepatology 1995;21:398-402
77. Underhill JA, Donaldson PT, Doherty DG, et al. HLA DPB polymorphism in primary sclerosing cholangitis and primary biliary cirrhosis. Hepatology 1995;21:959-962
78. Seki T, Kiyosawa K, Ota M, et al. Association of primary biliary cirrhosis with human leukocyte antigen DPB1*0501 in Japanese patients. Hepatology 1993;18:73-78
79. Selinger MJ, Matloff DS, Kaplan MM. Gamma-glutamyl transpeptidase activity in liver disease: serum elevation is independent of hepatic GGTP activity. Clin Chim Acta 1982;125:283-290
80. Aitman TJ, Todd JA. Molecular genetics of diabetes mellitus. Baillieres Clin Endocrinol Metab 1995;9:631-656
81. Jones DE, Watt FE, Grove J, et al. Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. J Hepatol 1999;30:232-236
82. Gordon MA, Oppenheim E, Camp NJ, et al. Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region. J Hepatol 1999;31:242-247
83. Zappala F, Grove J, Watt FE, et al. No evidence for involvement of the interleukin-10-592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis. J Hepatol 1998;28:820-823
84. Gregory WL, Daly AK, Dunn AN, et al. Analysis of HLA-class-II-encoded antigen-processing genes TAP1 and TAP2 in primary biliary cirrhosis. QJM 1994;87:237-244
85. Graham AM, Dollinger MM, Howie SE, Harrison DJ. Identification of novel alleles at a polymorphic microsatellite repeat region in the human NRAMP1 gene promoter: Analysis of allele frequencies in primary biliary cirrhosis. J Med Genet 2000;37:150-152
86. Vilagut L, Vila L, Vinas O, et al. Cross reactivity of anti-Mycobacterium gornadae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. J Hepatol 1994;21:673-677
87. O'Donohue J, Fidler H, Garcia-Barcelo M, et al. Mycobacterial DNA not detected in liver sections from patients with primary biliary cirrhosis. J Hepatol 1998;28:433-438
88. Nishio A, Neuberger JM, Gershwin ME. Management of patients with primary biliary cirrhosis. BioDrugs 1999;12:159-173
89. Stemerowicz R, Hopf U, Moller B, et al. Are antimitochondrial antibodies in primary biliary cirrhosis induced by R(rough)-mutants of enterobacteriaceae? Lancet 1988;2:1166-1170
90. Hopf U, Moller B, Stemerowicz R, et al. Relation between Escherichia coli R(rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis. Lancet 1989;2:1419-1422
91. Burroughs AK, Rosenstein IJ, Epstein O, et al. Bacteriuria and primary biliary cirrhosis. Gut 1984;25:133-137
92. Butler P, Valle F, Hamilton-Miller JM, et al. M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria. J Hepatol 1993;17:408-414
93. Wadstrom T, Ljungh A, Willen R. Primary biliary cirrhosis and primary sclerosing cholangitis are of infectious origin! Gut 2001;49:454
94. Olsson R, Bjornsson E, Backman L, et al. Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. J Hepatol 1998;28:426-432
95. Kolbert CP, Persing DH. Ribosomal DNA sequencing as a tool for identification of bacterial pathogens. Curr Opin Microbiol 1999;2:299-305
96. Nilsson HO, Taneera J, Castedal M, et al. Identification of Helicobacter pylori and other Helicobacter species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis. J Clin Microbiol 2000;38:1072-1076
97. Hiramatsu K, Harada K, Tsuneyama K, et al. Amplification and sequence analysis of partial bacterial 16S ribosomal RNA gene in gallbladder bile from patients with primary biliary cirrhosis. J Hepatol 2000;33:9-18
98. Tanaka A, Prindiville TP, Gish R, et al. Are infectious agents involved in primary biliary cirrhosis? A PCR approach. J Hepatol 1999;31:664-671
99. Garry RF, Fermin CD, Hart DJ, et al. Detection of a human intracisternal A-type retroviral particle antigenically related to HIV. Science 1990;250:1127-1129
100. Mason AL, Xu L, Guo L, et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 1998;351:1620-1624
101. Fox RI. Sjogren syndrome. Curr Opin Rheumatol 1995;7:409-416
102. Triger DR. Primary biliary cirrhosis: an epidemiological study. BMJ 1980;281:772-775
103. Chetwynd A, Diggle P, Jarner M. Evidence for spatial variation in risk and of spatial clustering in PBC. Hepatology 1999;30:407A
104. Medzhitov R, Janeway CA Jr. How does the immune system distinguish self from nonself? Semin Immunol 2000;12:185-88; discussion 257-344
105. Powell JJ, Van de Water J, Gershwin ME. Evidence for the role of environmental agents in the initiation or progression of autoimmune conditions. Environ Health Perspect 1999;107(Suppl 5):667-672
106. Rose NR. Viral damage or molecular mimicry placing the blame in myocarditis. Nat Med 2000;6:631-632
107. Sinha A, Clatch RJ, Stuck G, et al. Isoflurane hepatotoxicity: a case report and review of the literature. Am J Gastroenterol 1996;91:2406-2409
108. Rao T, Richardson B. Environmentally induced autoimmune diseases: potential mechanisms. Environ Health Perspect 1999;107 (Suppl 5):737-742
109. Njoku D, Laster MJ, Gong DH, et al. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg 1997;84:173-178
110. Gut J, Christen U, Frey N, et al. Molecular mimicry in halothane hepatitis: biochemical and structural characterization of lipoylated autoantigens. Toxicology 1995;97:199-224
111. Bourdi M, Chen W, Peter RM, et al. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 1996;9:1159-1166
112. Long SA, Quan C, Van de Water J, et al. Immunoreactivity of organ mimetopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. J Immunol 2001;167:2956-2963
113. Sasaki M, Ansari A, Pumford N, et al. Comparative immunoreactivity of anti-trifluoroacetyl (TFA) antibody and anti-lipoic acid antibody in primary biliary cirrhosis: searching for a mimic. J Autoimmun 2000;15:51-60